63 results about "Benzalkonium chloride" patented technology

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

New liquid compositions are described for the relief of the xerostomia and the treatment of associated disorders, in which the compositions contain: a) saline saliva substitute agents selected from the group consisting of sodium chloride, potassium chloride, sodium bicarbonate, monobasic potassium phosphate, and dibasic phosphate potassium; b) saliva production stimulation agents selected from the group consisting of citric acid or its alkali metal salts and malic acid or its alkali metal salts; c) oral antiseptics selected from the group consisting of triclosan, chlorhexidine and its salts, benzalkonium and its salts, and cetylpyridinium chloride; d) anticariogenic agents selected from the group consisting of fluoride sodium, sodium monofluorophosphate, and xylitol; and e) oral mucosa protective agents selected from the group consisting of vitamin E acetate, panthenol, dipotassium glycyrrhizinate and extracts of aloe vera.The aforementioned compositions are presented in the form of mouthwashes, sprays, oral gels, and toothpastes.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

New liquid compositions are described for the relief of the xerostomia and the treatment of associated disorders, in which the compositions contain: a) saline saliva substitute agents selected from the group consisting of sodium chloride, potassium chloride, sodium bicarbonate, monobasic potassium phosphate, and dibasic phosphate potassium; b) saliva production stimulation agents selected from the group consisting of citric acid or its alkali metal salts and malic acid or its alkali metal salts; c) oral antiseptics selected from the group consisting of triclosan, chlorhexidine and its salts, benzalkonium and its salts, and cetylpyridinium chloride; d) anticariogenic agents selected from the group consisting of fluoride sodium, sodium monofluorophosphate, and xylitol; and e) oral mucosa protective agents selected from the group consisting of vitamin E acetate, panthenol, dipotassium glycyrrhizinate and extracts of aloe vera. The aforementioned compositions are presented in the form of mouthwashes, sprays, oral gels, and toothpastes.

Trans-epithelial osmotic collyrium for the treatment of keratoconus by corneal cross-linking with UV rays, of the type consisting of a riboflavin-based solution and an absorption enhancement adjuvant consisting of benzalkonium chloryde (BAC). The solution has a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution and contains a BAC concentration accordingly ranging between 0.005% and 0.035%.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

A saline liquid for treating allergic rhinitis by using it to flush nasal cavity contain proportionally sodium chloride, mint oil, polyoxyvinyl sorbitan monooleate, benzalkonium bromide and distilled water.

The invention discloses a hygienic disinfectant moist towelette which comprises a piece of spunlace non-woven cloth and moist towelette liquid, wherein the moist towelette liquid is formed by honeysuckle water extract, benzalkonium bromide, propylene glycol, sodium methyl paraben and ultrapure water. The hygienic disinfectant moist towelette has the disinfection function, and cannot do harm to skin.

The present invention provides hemostatic and antibacterial products, including solution, dressing and bandage. The hemostatic and antibacterial products contains setose thistle herb extract in 1-30.61 wt%, zephiran chloride in 0.1-0.5 wt%, and optional local anesthetic in 1-2 wt% and / or surfactant in 0.1-0.5 wt%. The production process of the hemostatic and antibacterial products is also provided.

The present invention provides an antiviral composition and system for using the same, wherein the antiviral composition includes between about 0.1 to about 0.3 wt % of antimicrobial agent such as benzalkoniumchloride, between about 0.1 to about 1 wt % of chlorinated phenol compound, such as parachlorometaxylenol, between about 0.1 to about 3 wt % of hydrogen peroxide, and at least about 60 wt % aqueous solvent.

The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and / or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term.

Kits and methods for treating disordered tissue caused by a virus in a mammal involve co-administration of a systemic anti-virus drug and topically administering an anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the disordered tissue surface and allow the anti-infective agent to kill viruses at the disordered tissue site. The anti-infective composition reduces the time and / or number of dosages required for the systemic anti-virus drug to treat the disordered tissue in the absence of topically administering the anti-infective composition. It also reduces or eliminates incidences of post-treatment neuralgia.

The invention relates to eye drops suitable for corneal limbal stem cell deficiency and a preparation method. The eye drops comprise the following components: 1-40 mg / L of human adipose-derived stem cell exosome, and auxiliary materials including 0.5-2 g / L of sodium hyaluronate, 0.5-3 g / L of vitamin B6, 0.05-0.3 g / L of benzalkonium chloride and the balance of medical normal saline, and the pH value is 6.5-7.5. The eye drops provided by the invention have the remarkable effect of treating the corneal limbal stem cell deficiency.

The invention discloses eye drops and a preparation method thereof, and particularly relates to bromfenac sodium hydrate eye drops and a preparation method thereof. The bromfenac sodium hydrate eye drops comprise the following constituents in percentage by weight: 0.1-0.2% of bromfenac sodium hydrate, 0.1-0.3% of Tween-80, 1-5% of povidone, 0.01-0.03% of edetate disodium, 0.2-0.5% of anhydrous sodium sulfite, 0.01-0.02% of benzalkonium bromide, 0.005-0.02% of boric acid, 0.005-0.02% of borax, 0.002-0.01% of sodium hydroxide, and the balance of water.

The present invention provides an antiviral composition and system for using the same, wherein the antiviral composition includes between about 0.1 to about 0.3 wt % of antimicrobial agent such as benzalkoniumchloride, between about 0.1 to about 1 wt % of chlorinated phenol compound, such as parachlorometaxylenol, between about 0.1 to about 3 wt % of hydrogen peroxide, and at least about 60 wt % aqueous solvent.

A diflucan eye drops for treating fungal injection of eye is prepared from diflucan and propanediol through mixing, grinding, adding the water for injection, dissolving benzalkonium chloride in water for injection, mixing and stirring.

The present invention provides a Chinese medicinal washing lotion for the prevention and treatment of edeitis, which is prepared from alcohol and water extracts or pure water extracts of five kinds of Chinese medicinal herbs: Chinese globeflower, cnidium fruit, flavescent sophora root, honeysuckle flower and borneo camphor, as well as 1.5-3.8mg / 100ml of benzalkonium bromide or chlorhexidine, and right amount of foaming agent within human acceptability.

There is provided according to the invention an aqueous composition having pH between 4 and 7 comprising (i) glucagon at a concentration of 0.05% w / v or more and (ii) a cationic surfactant selected from benzalkonium salts and benzethonium salts as solubilizing agent in an amount sufficient to dissolve the glucagon in the composition.

The invention discloses a preparation technology of disodium adenosine triphosphate capable of reducing energy consumption. An appropriate amount of room temperature reverse osmosis water is used for dissolving adenosine to prepare an adenosine solution, the energy consumption is saved by 15% or higher, the operation is simple, and the damage to enzymes is effectively avoided. In the prior art, magnesium sulfate is selectively used as an enzymatic reaction metal ionic compound in a biochemical reaction, but the adsorption capacity of strong basic anion resin used in a subsequent technology for sulfate ions is extremely high, a great difficulty is brought for later resin regeneration treatment, and new foreign ions can be introduced; however, when magnesium chloride is used for replacing the magnesium sulfate, the adsorption capacity of strong basic anion resin for chloride ions is weaker than that of strong basic anion resin for sulfate ions, the later resin regeneration treatment is facilitated, and new foreign ions cannot be introduced. According to the preparation technology, benzalkonium bromide is used as an active agent; the benzalkonium bromide is a nontoxic and innocuous disinfectant , and the difficulty is not increased for later treatment, so that the benzalkonium bromide is a reasonable substitute; a two-stage method is adopted for vacuum drying, so that not only is the pollution avoided, but also the time is saved.

This invention relates to an improved smudge free sanitary sheet made of waste paper and a process of preparing the same through processing the surplus newsprint and mors precisely processing used / recycled paper. The sanitary sheets are prepared by the process steps of collecting pre -consumer overprint or post consumer read newspapers; grading the collected waste newspaper; drying and sterilizing the graded newspaper by applying ultraviolet, infrared and / or gamma rays; trimming and cutting the dried sterilized sheets in appropriate sizes; applying on atieast one of the sides of the waste newspaper an aqueous coating comprising of a mixture of resin such as bleached shellac, a dye, a germicide such as Benzaikonium Chloride (BC) and / or PCMX (Chloroxylenol), a safe colour, a known deodorant and optionally cosmetic chemicals such as emollient and a foaming agent such as a detergent.; The improved sanitary sheeets prepaid by the present cost effective invention has taken care of any toxic effect on human skin to make those hygenic and aesthetic and the discarded sheets being biodegradable, the present invention is environment friendly. The sanitary sheets from present invention has various wide applications such as a single use barrier in outpatient beds of clinics or on x-ray tables, safe paper bags for carrying dry stuff, a mat on a publicly used seat like gyrn, safe pet care , paper towel, toilet paper, sanitary napkin, child diapers, adult incontinence products etc.

The present invention provides a preservative composition for protecting ophthalmic solutions from microbial attack comprising a combination of benzalkonium ion and An oxy-chlorite moiety, e.g. purite wherein the combined concentrations of benzalkonium ion and An oxy-chlorite moiety, e.g. purite in said composition is sufficient to provide protection against microbial attack when said composition is added to an ophthalmic solution as compared to said ophthalmic solution having the same concentration of benzalkonium ion and An oxy-chlorite moiety, e.g. purite, alone.

The invention discloses a benzalkonium bromide / sodium chloride flushing fluid. Every 1000L of flushing fluid is composed of the following components: 40-60g of benzalkonium bromide, 8.55-9.45kg of sodium chloride and the balance of water. Quality evaluation results prove that the flushing fluid has strong bacteriostatic action on Escherichia coli and Staphylococcus aureus, has no obvious irritation to the skin and eyes and is favorable in stability, thereby having wide clinical application prospects.

The invention discloses a Chinese medicine skin-disinfecting wet wipe. The Chinese medicine skin-disinfecting wet wipe is composed of a spunlace nonwoven fabric and wipe solution, wherein the wipe solution is prepared from ethylene diamine tetraacetic acid, chlorogenic acid, benzalkonium bromide, propanediol, sodium methyl parahydroxybenzoate and ultrapure water.

The invention discloses a compound dandelion wet wipe, which is composed of spunlaced nonwoven fabric and a wet wipe liquid. The wet wipe liquid comprises a honeysuckle extract, a Forsythia suspensa extract, a dandelion extract, benzalkonium bromide, propylene glycol, sodium methyl p-hydroxybenzoate, and ultra-pure water. The compound dandelion wet wipe provided by the invention has a bactericidal effect, and has no damage to the skin.

The invention provides a collective disinfectant for inhibiting viruses and pathogenic bacteria. The collective disinfectant is prepared from a bactericide, fullerene, nano tourmaline, a Chinese herbal medicine extract, fresh bamboo juice, phosphorylated titanium dioxide and water. The invention also provides a preparation method of the collective disinfectant for inhibiting viruses and pathogenicbacteria, which comprises the following steps: adding the bactericide, fullerene and Chinese herbal medicine extract into water, and uniformly stirring to obtain a mixed solution A; uniformly mixingnano tourmaline, phosphorylated titanium dioxide and fresh bamboo juice to obtain a mixed solution B; and adding the mixed solution B into the mixed solution A in a stirring state, and fully mixing toobtain a collective disinfectant product. According to the invention, benzalkonium chloride is used as a main body bactericide, and a plurality of plant traditional Chinese medicinal material extracts, health-care functional components and a plurality of auxiliary materials for enhancing the functions of killing viruses and harmful bacteria are added.

The invention discloses a fiber oil agent for reducing frictional static electricity. The fiber oil agent per kilogram comprises the following components in part by weight, 50.0-120.0g of fatty alcohol-polyoxyethylene ether, 100.0-180.0g of benzalkonium bromide, 50.0-160.0g of alkylphenol ethoxylates, 40.0-70.0g of polyoxyethylene alkyl phosphate potassium, 50.0-70.0g of fatty acid triglyceride, 20.0-40.0g of butyl cellosolve, 10.0-25.0g of fatty acid sorbitan, 5.0-10.0g of imidazoline and the rest mineral oil.

The invention discloses a compound honeysuckle flower wet tissue which is composed of a spunlace nonwoven fabric and a wet tissue solution, wherein the wet tissue solution is composed of honeysuckle flower extract, kuh-seng extract, taraxacum extract, benzalkonium bromide, propanediol, sodium methyl p-hydroxybenzoate and ultrapure water. The wet tissue has a bactericidal action and does not hurt the skin.

The invention discloses a compound asparticitin gutta and making method, which comprises the following parts: aspartic acid, vitamin B6, glycyrrhizin dipotassium, naphazoline hydrochloride, neostigmine methylsulfate, maleic chlorobenzenenamin, polysorbate 80, sodium chloride, menthol, benzachloridamine, sodium hydroxide solution and injecting water. The invention paves basis for scaling manufacturing of the compound asparticitin gutta further, which improves the productivity with stable content of maleic chlorobenzenenamin.